WHO panel gives go-ahead for monoclonal antibody therapy on two covid categories
The treatment combining the antibodies casirivimab and imdevimab has been recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group panel of international experts
NEW DELHI : A World Health Organization (WHO) panel on Friday gave its green signal to monoclonal antibodies therapy for management of two categories of covid-19 patients. A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group (GDG) panel of international experts. Casirivimab and imdevimab are monoclonal antibodies that when used together bind to the SARS-CoV-2 spike protein, neutralizing the virus’s ability to infect cells.